Adjuvanted Virus-Mimicking Nanoparticle HIV Vaccine
Document text
Principal Investigator: XU LI Organization: ZYMERON CORPORATION Fiscal Year: 2021 Award: $300,000 Funding agency: National Institute of Allergy and Infectious Diseases Particle-based Co-delivery of HIV immunogens as Next-generation HIV Vaccines: Tailored immunogens (such as Envs, monomers, native and/or native-like trimers, nucleic acids/RNA such as mRNAs, self-amplifying RNAs) combined with an effective multivalent antigenic display on nanoparticles for delivery may provide a strategy to promote strong and long-lived neutralizing antibody responses against HIV and direct affinity maturation toward HIV neutralizing antibodies. The objective of this contract is to develop a novel nanoparticle delivery system to elicit potent and long-lasting antibody response and broadly neutralizing activity against HIV. Terms: <AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Adjuvant><Affinity><Antibody Response><Antigens><Contracting Opportunities><Contracts><HIV><HIV vaccine><HIV/AIDS Vaccines><Human Immunodeficiency Viruses><LAV-HTLV-III><Lymphadenopathy-Associated Virus><Messenger RNA><Non-Polyadenylated RNA><Nucleic Acids><RNA><RNA Gene Products><RNA amplification><Ribonucleic Acid><STING agonists><System><Testing><Vaccines><Virus><Virus-HIV><base><human immunodeficiency virus vaccine><immunogen><mRNA><monomer><nano particle><nano particle delivery><nano-sized particle><nanoparticle><nanoparticle delivered><nanoparticle delivery><nanosized particle><neutralizing antibody><next generation><novel><particle>